^
Association details:
Biomarker:No biomarker
Cancer:Glioblastoma
Drug:Byvasda (bevacizumab biosimilar) (VEGF-A inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Title:

Innovent Announces the NMPA Granted New Indication Approval for BYVASDA (Bevacizumab Biosimilar) for the Treatment of Adult Recurrent Glioblastoma

Published date:
12/28/2020
Excerpt:
Innovent Biologics, Inc. (Innovent)...today announces that BYVASDA (bevacizumab biosimilar), a recombinant humanized anti-VEGF monoclonal antibody drug independently developed by Innovent, has been officially approved by the National Medical Products Administration (NMPA) of China for the treatment of adult recurrent glioblastoma...